This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: F20.4 (post-schizophrenic depression) | Special Copayment Reduction: V161 (severe intractable disease, copayment reduced for 5 years after registration) |
| B. Synonyms | Post-schizophrenic depression |
| C. Adult onset | Likelihood of first onset in adulthood: high - post-schizophrenic depression is a depressive episode occurring after schizophrenia has already developed, so it occurs in patients within the age range of schizophrenia onset (mainly adulthood). It may appear within months to years after the first onset of schizophrenia, and also occurs in mid-adulthood. |
| 1. History | Bleuler's description of "reactive depression" after schizophrenia → McGlashan and Carpenter's concept of "postpsychotic depression" → classified independently as F20.4 in ICD-10 → handled as a specifier without a separate code in DSM-5. |
| 2. Causes | Complex factors including the pathology of schizophrenia itself, antipsychotic drugs (parkinsonism-related depression, akathisia), psychological reaction (despair after increased insight), and experiences of social loss. |
| 3. Genetics | Genetic overlap between schizophrenia and depressive disorder (shared risk genes); depression vulnerability genes such as the serotonin transporter (5-HTTLPR) polymorphism may be involved. |
| 4. General epidemiology | About 25-50% of schizophrenia patients experience a depressive episode during the course; those meeting ICD-10 criteria for F20.4 are a portion of these; occurs most often in the early remission phase after the active phase of schizophrenia. |
| 5. Pathophysiology | Dopamine reduction (drug effect, negative symptoms) and serotonin abnormalities contribute to depression; subjective distress from akathisia and motor side effects; psychological grief reaction accompanying increased insight. |
| 6. Symptoms | Depressed mood, anhedonia, decreased energy, guilt, and suicidal ideation are the core; residual positive symptoms (mild delusions, auditory hallucinations) accompany; distinguishing from negative symptoms is a clinical challenge. |
| 7. Signs | Clinically significant depression score on the CDSS (Calgary Depression Scale for Schizophrenia); psychomotor retardation (differentiation from akathisia needed); suicide-related behavioral signs. |
| 8. Screening | Systematic screening for depression in schizophrenia patients with the CDSS; assessment of depressive symptoms is essential at every schizophrenia follow-up visit; suicide risk assessment in parallel. |
| 9. Diagnosis | ICD-10 F20.4: a depressive episode (ICD-10 depression criteria) lasting 2 weeks or more together with residual positive symptoms after the active phase of schizophrenia; differentiation from schizoaffective disorder, drug side effects (akathisia), and negative symptoms is essential. |
| 10. Treatment | Maintain antipsychotics (choose drugs with antidepressant effect such as aripiprazole and quetiapine); add an SSRI if needed; resolve akathisia (propranolol, BZD, medication adjustment); adjunctive CBT. |
| 11. Prognosis | With appropriate treatment, remission of the depressive episode is possible, but the risk of relapse is high; suicide risk is highest at this stage over the entire course of schizophrenia. |
| 12. Prevention | Intensive monitoring in the early remission phase after the active phase of schizophrenia; active management of antipsychotic side effects (akathisia, EPS); psychological support intervention after improved insight. |
| 13. References | Siris SG. Depression in schizophrenia: perspective in the era of "atypical" antipsychotic agents. Am J Psychiatry. 2000 … and 9 other papers |
The history of post-schizophrenic depression traces the development of recognition of the clinical significance of depressive symptoms in schizophrenia. In 1911, Eugen Bleuler described "reactive depression" appearing after active-phase symptoms in schizophrenia patients. He observed that this depressive state could be related to the patient's increasing awareness of their own illness, but did not systematize it as a separate clinical entity.
In 1976, Thomas McGlashan and William Carpenter systematically described the concept of "postpsychotic depression" and emphasized that it is an important clinical phenomenon in the course of schizophrenia. They argued that the depressive state appearing after active-phase symptoms of schizophrenia have resolved is an independent clinical phenomenon distinct from simple negative symptoms or antipsychotic side effects. Subsequently, several researchers explored the prevalence and characteristics of postpsychotic depression and its relation to suicide risk.
In 1992, the WHO ICD-10 classified "post-schizophrenic depression" as an independent subtype under F20.4. This reflected the international recognition that the condition is clinically important and requires separate diagnostic attention. However, DSM-IV of the same period took the approach of stating a history of schizophrenia when diagnosing major depression, without a separate code.
DSM-5 in 2013 abolished the schizophrenia subtypes and did not provide a separate code corresponding to post-schizophrenic depression. DSM-5 handles it by adding a "depressive mood specifier" to the schizophrenia diagnosis or by listing a separate major depressive disorder diagnosis alongside. In contrast, ICD-10 retains F20.4, and this code is used in clinical practice in Korea.
One of the main reasons for increased clinical interest in post-schizophrenic depression is suicide risk. Research findings that one of the periods of highest suicide risk in schizophrenia patients is the partial remission stage after active-phase symptoms, that is, the period when post-schizophrenic depression appears, have emphasized the clinical importance of this diagnosis.
The cause of post-schizophrenic depression involves a combination of biological, psychological, and social factors and is difficult to explain by a single cause.
Biological factors - antipsychotic side effects: Extrapyramidal symptoms (EPS) and akathisia caused by first-generation antipsychotics induce subjective distress and dysphoria, creating a depression-like state. Akathisia, with extreme inner restlessness and motor urge, is strongly associated with suicidal impulses. Subthreshold parkinsonian symptoms (bradykinesia, hypoactivity) due to excessive dopamine blockade create a clinical picture that is difficult to distinguish from negative symptoms or depression.
Biological factors - the pathology of schizophrenia itself: Some researchers view post-schizophrenic depression as part of the pathology of schizophrenia itself, with serotonin and dopamine system abnormalities raising vulnerability to depression. In schizophrenia, prefrontal cortex dopamine hypoactivity and serotonin system abnormalities may act as an underlying vulnerability to depression.
Psychological factors: When insight increases as active-phase symptoms resolve, the patient comes to face the reality of having a serious mental illness. In this process, a sense of loss, awareness of stigma, and a grief reaction to the loss of job, relationships, and future plans can lead to depression. This psychological process, also described as an "existential crisis," is an important psychological basis of post-schizophrenic depression.
Social factors: Social stigma toward mental illness, job loss, shrinking interpersonal relationships, and financial hardship form the social basis of depression. Lack of family support and social isolation are factors that worsen depression.
The genetics of post-schizophrenic depression is understood in the context of genetic overlap between schizophrenia and depressive disorder.
Genetic overlap between schizophrenia and depressive disorder: Large-scale GWAS studies have confirmed considerable overlap of genetic risk factors between schizophrenia and major depressive disorder. This suggests that some schizophrenia patients may also carry genetic vulnerability to depression. In individuals with high genetic risk of schizophrenia, vulnerability to depression may also be elevated.
Serotonin-related genes: The promoter polymorphism (5-HTTLPR) of the serotonin transporter gene (SLC6A4) is well known as a gene regulating depressive response in stressful situations. Some studies have suggested that this variant may be associated with the occurrence of postpsychotic depression in schizophrenia patients, but conclusive evidence is still lacking.
HPA axis-related genes: Variants of stress-response genes of the hypothalamic-pituitary-adrenal (HPA) axis (FKBP5, CRH, etc.) are associated with stress-related vulnerability to depression. HPA axis abnormalities have been reported in schizophrenia patients, and these abnormalities may contribute to the occurrence of post-schizophrenic depression.
Determining the exact prevalence of post-schizophrenic depression varies from study to study because of variability in diagnostic criteria and difficulty differentiating it from negative symptoms and drug side effects.
Prevalence: The proportion of schizophrenia patients who experience depressive symptoms of some form during the course reaches about 25-50%. Of these, clear depressive episodes meeting the ICD-10 F20.4 criteria are estimated at about 10-30%. With a broader definition of depressive symptoms, more than 50% of schizophrenia patients may qualify.
Timing of onset: Post-schizophrenic depression typically occurs within weeks to months after active-phase symptoms of schizophrenia remit. It appears most often at the boundary between the late active phase and the early remission phase, and this period is sometimes called the "window of depression." In chronic schizophrenia patients it can also occur repeatedly in each remission phase after reactivation.
Sex and age characteristics: The rate of depressive episodes is slightly higher in female schizophrenia patients, consistent with the generally higher vulnerability to mood disorders in women. There are reports that the frequency of depressive episodes is higher in paranoid schizophrenia than in other subtypes, which is explained by insight being relatively preserved in paranoid-type patients, so the psychological response to their own condition is stronger.
Suicide risk: Post-schizophrenic depression is the stage with the highest suicide risk over the entire course of schizophrenia. The completed suicide rate in schizophrenia patients is reported at about 4-10%, and a considerable number of these occur at the postpsychotic depression stage. Suicide risk management is the top priority in the clinical management of this diagnosis.
The pathophysiology of post-schizophrenic depression is understood as a complex model in which neurobiological bases and psychological mechanisms interact.
Dopamine-serotonin interaction: Excessive dopamine D2 blockade by antipsychotics causes mesolimbic dopamine reduction, which leads to decreased pleasure experience (anhedonia) and decreased motivation (avolition). This mechanism blurs the boundary between negative symptoms and depressive symptoms. Abnormal serotonin 5-HT2A receptor function has been reported in schizophrenia patients and contributes to vulnerability to depression.
Akathisia and subjective distress: Antipsychotic-induced akathisia is characterized by inner restlessness, motor urge, and extreme dysphoria, which are strongly associated with depression and suicidal impulses. Subjective distress from akathisia often leads to depressed mood and thoughts of wanting to die, so recognition and treatment of akathisia are decisive in preventing post-schizophrenic depression.
Increased insight and psychological reaction: The process in which the patient's insight is restored as active-phase symptoms decrease with treatment paradoxically induces depression. The realization of having a serious chronic mental illness, the sense of loss that life plans from before onset (study, career, marriage) have collapsed, and awareness of stigma are the core of this psychological process. It is also described as "escape depression" or "insight depression."
HPA axis abnormality: Abnormal cortisol response has been reported in schizophrenia patients, and vulnerability to depression may increase during the normalization of HPA axis function in the remission phase after the active phase. This mechanism shares a pathway similar to the occurrence of stress-related depression.
The clinical symptoms of post-schizophrenic depression are similar to those of ordinary depression, but form a complex clinical picture in that they coexist with residual schizophrenia symptoms.
Core depressive symptoms: Persistent depressed mood (sadness, emptiness, hopelessness), anhedonia (loss of interest and pleasure in previously enjoyed activities), decreased energy and fatigue, psychomotor retardation (overall slowing of thought and movement), decreased concentration, and sleep disturbance (insomnia or hypersomnia) appear. The diagnostic criteria are met when these symptoms last 2 weeks or more and cause functional decline.
Suicide-related symptoms: Feelings of worthlessness, guilt ("I am a burden to my family"), a wish to die, suicidal ideation, and suicide plans may appear. Bearing in mind that the post-schizophrenic depression stage is the period of highest suicide risk in the course of schizophrenia, suicide risk should be actively assessed in all patients.
Accompanying residual positive symptoms: According to the ICD-10 criteria, some schizophrenia symptoms (residual delusions, mild auditory hallucinations) may still be present in post-schizophrenic depression, but they do not dominate the clinical picture. These residual symptoms interact with depressive symptoms and increase the complexity of the symptoms.
Distinction from negative symptoms: The negative symptoms of schizophrenia (avolition, alogia, affective blunting) and depressive symptoms (decreased energy, anhedonia, depressed mood) are very difficult to distinguish clinically. The presence of subjective feelings of sadness, guilt, and suicidal ideation strongly suggests depressive symptoms, whereas overall blunting of emotion and decreased activity without subjective dysphoria are closer to negative symptoms. The CDSS (Calgary Depression Scale for Schizophrenia) is a standard tool developed to help with this distinction.
The clinical signs of post-schizophrenic depression appear on the mental status examination as a coexistence of a depressive syndrome and residual schizophrenia symptoms.
Mental status examination: Depressed mood is prominent, and sadness, hopelessness, and tears are observed in facial expression and behavior (emotional responsiveness is present, in contrast to the affective blunting of negative symptoms). Spontaneous speech is reduced and answers are brief. Guilt and self-deprecating content are prominent in thought. Suicidal ideation or plans may be present.
CDSS score: The Calgary Depression Scale for Schizophrenia (CDSS) is a 9-item scale designed to assess depressive symptoms in schizophrenia patients separately from negative symptoms and drug side effects. A CDSS total score of 5 or more is widely used as the criterion for clinically significant depression. This scale was designed so that antipsychotic-induced apathy or EPS are not misclassified as depression.
Differentiating signs of akathisia: Akathisia is characterized by extreme inner restlessness and motor urge and causes subjective distress similar to depression. Assessment of akathisia with the Barnes Akathisia Rating Scale (BARS) is an essential differential step in diagnosing post-schizophrenic depression.
Physical symptoms: Insomnia, decreased (or increased) appetite, weight change, and psychomotor retardation are observed. These physical symptoms also need to be differentiated from antipsychotic side effects (weight gain, sedation).
Systematic screening for early detection of post-schizophrenic depression is essential for suicide prevention and improved quality of life.
Regular application of the CDSS: It is recommended to apply the CDSS regularly (at intervals of at least 3-6 months) from the time of entering the remission phase after the active phase of schizophrenia. Intensive assessment at least once a month at the transition between the active phase and the remission phase contributes to reducing suicide risk. When the CDSS score is 5 or more, an immediate clinical interview and suicide risk assessment must follow.
Integrated suicide risk assessment: Screening for depressive symptoms and suicide risk assessment are always performed together. The Columbia Suicide Severity Rating Scale (C-SSRS) or a structured suicide risk interview is the standard tool. History of past suicide attempts, impulsivity, substance use, and social isolation are factors raising suicide risk.
Concurrent assessment of akathisia: Assessment of akathisia (BARS) and EPS is performed alongside depression screening. Because resolving akathisia often leads to relief of depressive symptoms, it is clinically efficient to always perform the two assessments at the same time.
Quality of life assessment: Assessing subjective quality of life with the Schizophrenia Quality of Life Scale (SQLS), EQ-5D, etc. helps identify depression-related functional decline early.
Diagnosis of post-schizophrenic depression is a process of accurately grasping the course of schizophrenia and systematically excluding various differential diagnoses.
ICD-10 F20.4 diagnostic criteria: ① The patient must have met, in the past or at present, the criteria for schizophrenia (F20.0-F20.3 or F20.5-F20.9). ② Some schizophrenia symptoms are still present but do not dominate the clinical picture. ③ Depressive symptoms are in the foreground and meet the ICD-10 criteria for a depressive episode (F32). ④ Depressive symptoms last at least 2 weeks. Depression arising when schizophrenia has completely remitted is diagnosed as a separate depressive episode rather than F20.4.
Differential diagnosis: ① Schizoaffective disorder, depressive type (F25.1): schizophrenia symptoms and a depressive episode are met simultaneously, and depression precedes or first appears together with the schizophrenia symptoms. ② Drug-induced depression (antipsychotics): depression-like symptoms due to akathisia, EPS, sedation, and hyperprolactinemia are distinguished with the CDSS and BARS. ③ Negative symptoms: avolition and affective blunting lack a subjective feeling of sadness; the CDSS helps distinguish. ④ Depression due to physical illness: hypothyroidism, diabetes, anemia, etc. are excluded with blood tests.
Essential tests: CDSS and BARS assessment, suicide risk assessment (C-SSRS), blood tests (thyroid function, prolactin, blood glucose, anemia), drug levels (if applicable). Cognitive function assessment with neuropsychological testing if needed.
Treatment of post-schizophrenic depression is a stepwise approach that prioritizes optimizing antipsychotics and adds antidepressants and psychosocial treatment as needed.
Optimizing antipsychotics: First assess whether the current antipsychotic is causing akathisia or EPS, and if so consider reducing the dose or switching to a drug with a low likelihood of causing akathisia (quetiapine, aripiprazole, clozapine). Aripiprazole and quetiapine are second-generation antipsychotics with relatively good antidepressant effects and are preferred in post-schizophrenic depression. For treating akathisia, consider adding propranolol (40-120 mg/day), a benzodiazepine, or biperiden.
Adding an antidepressant: If depressive symptoms persist or are severe even after optimizing antipsychotics, add an SSRI (sertraline, fluoxetine, escitalopram) or an SNRI. SSRIs have a low risk of worsening positive symptoms of schizophrenia, and drug interactions are relatively predictable. After adding an antidepressant, evaluate response after 4-6 weeks, and if the response is sufficient, maintain for at least 6-12 months.
Psychotherapy: CBT is effective in correcting cognitive distortions related to guilt, hopelessness, and stigma. Individual recovery-oriented counseling, group therapy, and family support education play an adjunctive role in recovery of depressive symptoms and social function. When suicide risk is high, establishing a safety plan is essential.
Inpatient treatment: Inpatient treatment is needed for a severe depressive episode, high suicide risk, or physical risk such as refusal of food and drink. ECT can also be considered during hospitalization for severe treatment-resistant depression.
The prognosis of post-schizophrenic depression should be understood on two dimensions: the depressive episode itself and the underlying schizophrenia.
Short-term prognosis of the depressive episode: With appropriate treatment, remission of the depressive episode is possible, and about 50-70% of patients experience significant improvement of depressive symptoms with optimization of antipsychotics and antidepressant treatment. However, the relapse rate is high, making it difficult to maintain complete remission.
Suicide risk: Post-schizophrenic depression is the stage with the highest suicide risk in the course of schizophrenia. If the patient is left without adequate suicide risk assessment and management at this stage, it can lead to fatal consequences. Suicide prevention is the top treatment goal.
Effect on the underlying schizophrenia: Recurrent depressive episodes lead to declining social function, decreased antipsychotic adherence, and disconnection from community services, raising the risk of schizophrenia relapse. Active management of depressive symptoms also contributes to preventing schizophrenia relapse over the whole course.
Long-term course: Some studies report that recurrent post-schizophrenic depression may be associated with a transition from schizophrenia to the residual type. This suggests a pathway by which chronic depression accelerates functional decline. Ongoing depression monitoring and preventive antidepressant treatment may contribute to improved long-term prognosis.
Prevention of post-schizophrenic depression centers on intensive monitoring and management of precipitating factors during the high-risk stage (the transition from active phase to remission phase).
Active management of antipsychotic side effects: Because akathisia and EPS are major causes of depression, preventing them and recognizing and treating them early is the top priority. Choose second-generation drugs, which are less likely to cause EPS than high-potency first-generation antipsychotics, or apply akathisia prevention strategies (use the minimum effective dose, avoid rapid dose escalation).
Intensive monitoring in the early remission phase: The 6 months after active-phase symptoms resolve are the period of highest risk of developing depression. During this period, shorten the interval between outpatient visits (every 2-4 weeks) and perform the CDSS and suicide risk assessment regularly.
Psychological support with increased insight: Recognize the psychological distress patients experience as insight is restored, and provide psychological support for it (supportive counseling, psychoeducation) early. Stigma-reduction education, peer support, and recovery model-based counseling are helpful.
Strengthening social support: Restore social function and prevent isolation through vocational rehabilitation, educational support, and social skills training. Through family support education, prepare caregivers to recognize early signs of depressive symptoms and contact a specialist promptly.
Siris SG. Depression in schizophrenia: perspective in the era of "atypical" antipsychotic agents. Am J Psychiatry. 2000;157(9):1379-1389. DOI: 10.1176/appi.ajp.157.9.1379. PMID: 10964850.
Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990;3(4):247-251. DOI: 10.1016/0920-9964(90)90005-R. PMID: 2278986.
McGlashan TH, Carpenter WT Jr. Postpsychotic depression in schizophrenia. Arch Gen Psychiatry. 1976;33(2):231-239. DOI: 10.1001/archpsyc.1976.01770020065010. PMID: 1267086.
Barnes TR, Curson DA. Long-term depot antipsychotics: a risk-benefit assessment. Drug Saf. 1994;10(6):464-479. DOI: 10.2165/00002018-199410060-00006. PMID: 7917077.
Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet. 2022;399(10323):473-486. DOI: 10.1016/S0140-6736(21)01730-X. PMID: 35093236.
Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. DOI: 10.1016/S0140-6736(13)60733-3. PMID: 23810019.
Braw Y, Bloch Y, Mendelovich S, et al. Cognition in young schizophrenia outpatients: comparison of first-episode with multiepisode patients. Schizophr Bull. 2008;34(3):544-554. DOI: 10.1093/schbul/sbm115. PMID: 17959618.
Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005;62(3):247-253. DOI: 10.1001/archpsyc.62.3.247. PMID: 15753237.
National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. NICE guideline CG178. 2014 (updated 2019). Available at: https://www.nice.org.uk/guidance/cg178.
Birchwood M, Iqbal Z, Chadwick P, Trower P. Cognitive approach to depression and suicidal thinking in psychosis. 1. Ontogeny of post-psychotic depression. Br J Psychiatry. 2000;177:516-521. DOI: 10.1192/bjp.177.6.516. PMID: 11102325.